Evofem Biosciences
Developing and commercializing products that address unmet needs in women’s sexual and reproductive health.
San Diego, United States
43 employees
Post Ipo Equity
Total: $455.10M
Biopharma, Health Care +1
General Information
Get notified when Evofem Biosciences moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Evofem Biosciences
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Evofem Biosciences
Taxonomy: biopharmaceutical, women's health, reproductive health, contraceptives, prescription products, sexual health, innovative products, birth control, hormone-free, on-demand, vaginal gel, commercial-stage, unmet needs, Phexxi, Evofem Biosciences
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 1 | •••• •••• | 15 May 2024 |
| Post-IPO Equity | •••••• | - | 20 May 2022 | |
| Post-IPO Equity | •••••• | - | 18 May 2021 | |
| Post-IPO Equity | •••••• | - | 25 Mar 2021 | |
| Post-IPO Debt | •••••• | 1 |
|
15 Oct 2020 |
Latest News
View All
Evofem Biosciences Alternatives & Competitors
The UK's first by women, for women sexual health and wellbeing retailer
an inclusive sexual and reproductive health ecosystem and community for people with vaginas
-logo.jpg "Kindly (YC W22)"){kind=logo}
India’s Most loved Sexual Health Brand | Sensuality, Where Kindness Leads the Way ❤️
FAQ About Evofem Biosciences
Don't just browse. Track.
Signal Tracker monitors Evofem Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.